Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA vaccines and medicines company, announced it will release its Q3 2024 financial results on November 7, 2024, after market close. The company will also host a conference call and webcast at 4:30 pm ET on the same day to discuss the results and provide a corporate update. The call can be accessed domestically at 1-800-274-8461 and internationally at 1-203-518-9814 using the conference ID: ARCTURUS. A webcast link will be available for streaming.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 7, 2024.

Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call

• Thursday, November 7, 2024 @ 4:30 p.m. ET
• Domestic: 1-800-274-8461
• International: 1-203-518-9814
• Conference ID: ARCTURUS
• Webcast: Link

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE^®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241031211431/en/

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

IR@arcturusrx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When will Arcturus Therapeutics report its Q3 2024 financial results?

Arcturus Therapeutics will report its Q3 2024 financial results on November 7, 2024, after market close.

What time is Arcturus Therapeutics' Q3 2024 earnings conference call?

The Q3 2024 earnings conference call for Arcturus Therapeutics will be at 4:30 pm ET on November 7, 2024.

How can I access the Arcturus Therapeutics Q3 2024 earnings conference call?

The call can be accessed domestically at 1-800-274-8461 and internationally at 1-203-518-9814 with the conference ID: ARCTURUS.

Will there be a webcast for Arcturus Therapeutics' Q3 2024 financial results?

Yes, a webcast link will be available for streaming the conference call.